# Ipamorelin FAQ: Half-Life, Effects, Safety, and Regulatory Status

> Ipamorelin questions answered from the literature: half-life, how long it stays in your system, how long it takes to work, FDA status, side effects, and the CJC-1295 pairing. Direct, cited answers.

## How to reconstitute CJC-1295 ipamorelin 5mg?

Reconstitution means dissolving a lyophilized (freeze-dried) peptide powder in bacteriostatic water for research handling; this site does not provide preparation protocols or volumes. Note that the popular CJC-1295 + ipamorelin combination has never been tested as a combination in any controlled trial — its support is single-agent pharmacology only, and no human dosing basis exists for it [3].

## How long does ipamorelin stay in your system?

In the one human study, ipamorelin's terminal half-life was about 2 hours, with clearance 0.078 L/h/kg [2]. By the four-to-five-half-lives rule, the drug is largely cleared within roughly 8-10 hours. Detection in urine by anti-doping laboratories is a separate matter and can extend beyond the pharmacological effect [12]. Full detail is on the [how long does ipamorelin stay in your system](/half-life) page.

## How long does it take for ipamorelin to work?

The immediate action is fast: the growth-hormone pulse peaks about 40 minutes (0.67 hours) after a dose in the human pharmacokinetic study [2]. Community-reported effects such as deeper sleep are described over one to two weeks, but those are anecdotal, not clinical findings. See the [how long does it take for ipamorelin to work](/how-long-to-work) page for both timelines.

## What is the half-life of ipamorelin?

The terminal half-life is approximately 2 hours in healthy human volunteers, measured by intravenous population PK/PD modeling, alongside a clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. This is the single best-characterized human pharmacokinetic figure for the compound and the lead lens of this site.

## Is ipamorelin available in an oral form?

Ipamorelin itself is not orally bioavailable. Engineered analogs derived from ipamorelin achieved only about 10-55% oral bioavailability in dogs, illustrating the structural difficulty of making this peptide class orally active [8]. The routes used in research are intravenous, subcutaneous, intranasal, and intraperitoneal — not oral [2].

## What is ipamorelin?

Ipamorelin is a synthetic pentapeptide (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin / GHS-R1a receptor to release a pulse of growth hormone. Its founding characterization established it as the first highly GH-selective secretagogue — potent GH release without raising ACTH or cortisol [1]. It is a research chemical, not an approved drug.

## What does ipamorelin do for you?

In studies, ipamorelin triggers a discrete growth-hormone pulse via the ghrelin receptor, without the cortisol rise older peptides cause [1]. Beyond that measured action, it has no proven human benefit: the only Phase 2 trial, for postoperative ileus, missed its primary endpoint [3]. Community-reported effects exist but are anecdotal — see [the effects page](/effects).

## What is ipamorelin peptide?

Ipamorelin peptide is the same compound — a five-amino-acid (pentapeptide) growth hormone secretagogue. 'Peptide' simply notes that it is a short chain of amino acids. It mimics the body's hunger hormone ghrelin at the GHS-R1a receptor to release growth hormone, and is distinguished by its selectivity for GH over cortisol and prolactin [1].

## What are the risks of ipamorelin?

The documented risks are mostly gaps: no Phase 3 trial, no long-term human safety data, and a failed Phase 2 efficacy trial [3]. Mechanistically, GH-axis stimulation raises theoretical concerns around IGF-1 and proliferation, and a class-level rat study of a related agonist found heart-muscle damage over 28 days [6]. Cited cautions are on [the effects page](/effects).

## Does ipamorelin reduce belly fat?

No human trial has shown ipamorelin reduces belly fat. The relevant animal data are indirect: in a 2024 ferret study, ipamorelin inhibited chemotherapy-induced weight *loss* by about 24% [9], and community reports describe gradual leaning over weeks — but those are anecdotal and confounded by diet and training [3]. There is no controlled-trial evidence for fat reduction in humans.

## What are the downsides of ipamorelin?

The central downside is the evidence gap: its only Phase 2 trial failed its primary endpoint and it has never been approved [3]. Practical downsides reported by users include facial flushing, appetite increase, water retention, and injection-site irritation — all anecdotal [9]. Supply is also a concern, as research-grade material from unregulated sources has unverified purity.

## Why is ipamorelin being discontinued?

Ipamorelin was never an approved product to discontinue. Its clinical development effectively ended when the Phase 2 postoperative-ileus trial missed its primary endpoint (time to first tolerated meal 25.3 vs 32.6 hours, p=0.15) [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the 503A bulk-substances list, tightening compounding-pharmacy access [3].

## What does CJC-1295 and ipamorelin do?

In combination, CJC-1295 (a GHRH analog) and ipamorelin (a ghrelin-receptor peptide) are intended to release growth hormone through two complementary pathways at once [1]. The rationale is mechanistically sound, but there are no controlled trials of the combination for any outcome — its support is the separate single-agent pharmacology of each [3].

## Does ipamorelin increase IGF-1?

Not consistently in short studies. In the rat bone-growth study, ipamorelin raised bone-growth rate with no measurable change in total IGF-1, suggesting a partly local GH effect [4]. In sustained protocols, GH-axis stimulation can raise hepatic IGF-1, but this is context-dependent and was not elevated in the short rodent windows tested [1].

## How does CJC-1295 ipamorelin work?

CJC-1295 acts on the GHRH receptor while ipamorelin acts on the separate ghrelin/GHS-R1a receptor; both converge on pituitary cells to release growth hormone, so engaging both pathways can in principle produce a larger pulse than either alone [1]. This is a mechanistic rationale, not a trial-proven combination effect [3].

## How much CJC-1295 ipamorelin should I take?

This site does not provide human dosing. No approved dose exists, and the CJC-1295 + ipamorelin combination has never been studied in a controlled human trial, so any circulating 'stack' protocol has no peer-reviewed basis [3]. The studied human ipamorelin doses were all intravenous and clinic-administered [2].

## Does CJC-1295 ipamorelin work?

There is no controlled-trial evidence that the CJC-1295 + ipamorelin combination 'works' for anti-aging, fat loss, or muscle gain — those claims rest on mechanism and single-agent pharmacology [3]. Each peptide releases GH in studies [1], but the combination as marketed has not been tested against any clinical outcome in humans.

## Does ipamorelin make you hungry?

It can, by mechanism. Ipamorelin acts on the ghrelin receptor — the same receptor the body's natural hunger hormone uses — so increased appetite is an expected class effect, and some users report a hunger uptick after dosing [7]. Community accounts describe it as milder than with GHRP-6, but appetite increase is among the more mechanistically predictable effects.

## Will I gain weight on ipamorelin?

There is no human-trial answer. In mice, ipamorelin showed GH-independent increases in fat mass and leptin after two weeks [7], and its ghrelin-receptor mechanism can raise appetite — so weight gain is plausible by mechanism. But the only human trial measured bowel recovery, not body weight [3]. Community reports vary and are anecdotal.

## Does ipamorelin increase appetite?

By its mechanism, yes — ghrelin-receptor (GHS-R1a) agonists activate hypothalamic appetite centers and induce feeding in animal studies [7]. Users commonly report increased hunger in the hours after a dose, generally described as milder than with the older peptide GHRP-6 [7]. This is one of the more predictable effects given how the compound works.

## What does ipamorelin peptide do?

Ipamorelin peptide selectively activates the ghrelin/GHS-R1a receptor on the pituitary to release a single growth-hormone pulse, without the cortisol or prolactin rise caused by less selective peptides [1]. That measured hormonal action is its defining function; proven human therapeutic benefit does not exist, as the one Phase 2 trial failed [3].

## Does ipamorelin cause water retention?

Some users report mild, transient water retention and puffiness in the first few weeks, generally described as milder than with older GHRP compounds — but this is anecdotal, not from a controlled trial [3]. Mechanistically, GH excess is associated with sodium and fluid retention, which gives the reports a plausible basis without confirming them.

---

A pharmacokinetics-first due-diligence read of the ipamorelin record — the ~2-hour human half-life and the clearance figures logged as the one clean instrument reading, the failed Phase 2 endpoint and the 503A/WADA status entered straight from the register, and the community reports held to one side as unverified; no clinic behind the readout, no endorsement of any seller, and nothing here dosed, prescribed, or sold.